Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Jiannong Li, Keiryn Bennett, Alexey Stukalov, Bin Fang, Guolin Zhang, Takeshi Yoshida, Isamu Okamoto, Jae Young Kim, Lanxi Song, Yun Bai, Xiaoning Qian, Bhupendra Rawal, Michael Schell, Florian Grebien, Georg Winter, Uwe Rix, Steven Eschrich, Jacques Colinge, John Koomen, Giulio Superti-Furga & 1 others Eric B. Haura

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We hypothesized that elucidating the interactome of epidermal growth factor receptor (EGFR) forms that are mutated in lung cancer, via global analysis of protein-protein interactions, phosphorylation, and systematically perturbing the ensuing network nodes, should offer a new, more systems-level perspective of the molecular etiology. Here, we describe an EGFR interactome of 263 proteins and offer a 14-protein core network critical to the viability of multiple EGFR-mutated lung cancer cells. Cells with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) had differential dependence of the core network proteins based on the underlying molecular mechanisms of resistance. Of the 14 proteins, 9 are shown to be specifically associated with survival of EGFR-mutated lung cancer cell lines. This included EGFR, GRB2, MK12, SHC1, ARAF, CD11B, ARHG5, GLU2B, and CD11A. With the use of a drug network associated with the core network proteins, we identified two compounds, midostaurin and lestaurtinib, that could overcome drug resistance through direct EGFR inhibition when combined with erlotinib. Our results, enabled by interactome mapping, suggest new targets and combination therapies that could circumvent EGFR TKI resistance.

Original languageEnglish
Article number705
JournalMolecular Systems Biology
Volume9
DOIs
Publication statusPublished - Nov 5 2013

Fingerprint

Growth Factors
resistance mechanisms
Vulnerability
Epidermal Growth Factor Receptor
Receptor
Perturbation
Proteins
Lung Cancer
Protein
lung neoplasms
Lung Neoplasms
4'-N-benzoylstaurosporine
proteins
Protein-Tyrosine Kinases
Inhibitor
tyrosine
Cell
phosphotransferases (kinases)
Cells
Drug Resistance

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)
  • Applied Mathematics

Cite this

Li, J., Bennett, K., Stukalov, A., Fang, B., Zhang, G., Yoshida, T., ... Haura, E. B. (2013). Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Molecular Systems Biology, 9, [705]. https://doi.org/10.1038/msb.2013.61

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. / Li, Jiannong; Bennett, Keiryn; Stukalov, Alexey; Fang, Bin; Zhang, Guolin; Yoshida, Takeshi; Okamoto, Isamu; Kim, Jae Young; Song, Lanxi; Bai, Yun; Qian, Xiaoning; Rawal, Bhupendra; Schell, Michael; Grebien, Florian; Winter, Georg; Rix, Uwe; Eschrich, Steven; Colinge, Jacques; Koomen, John; Superti-Furga, Giulio; Haura, Eric B.

In: Molecular Systems Biology, Vol. 9, 705, 05.11.2013.

Research output: Contribution to journalArticle

Li, J, Bennett, K, Stukalov, A, Fang, B, Zhang, G, Yoshida, T, Okamoto, I, Kim, JY, Song, L, Bai, Y, Qian, X, Rawal, B, Schell, M, Grebien, F, Winter, G, Rix, U, Eschrich, S, Colinge, J, Koomen, J, Superti-Furga, G & Haura, EB 2013, 'Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms', Molecular Systems Biology, vol. 9, 705. https://doi.org/10.1038/msb.2013.61
Li, Jiannong ; Bennett, Keiryn ; Stukalov, Alexey ; Fang, Bin ; Zhang, Guolin ; Yoshida, Takeshi ; Okamoto, Isamu ; Kim, Jae Young ; Song, Lanxi ; Bai, Yun ; Qian, Xiaoning ; Rawal, Bhupendra ; Schell, Michael ; Grebien, Florian ; Winter, Georg ; Rix, Uwe ; Eschrich, Steven ; Colinge, Jacques ; Koomen, John ; Superti-Furga, Giulio ; Haura, Eric B. / Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. In: Molecular Systems Biology. 2013 ; Vol. 9.
@article{c87d6686f6a24f8eba43f3317d282f67,
title = "Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms",
abstract = "We hypothesized that elucidating the interactome of epidermal growth factor receptor (EGFR) forms that are mutated in lung cancer, via global analysis of protein-protein interactions, phosphorylation, and systematically perturbing the ensuing network nodes, should offer a new, more systems-level perspective of the molecular etiology. Here, we describe an EGFR interactome of 263 proteins and offer a 14-protein core network critical to the viability of multiple EGFR-mutated lung cancer cells. Cells with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) had differential dependence of the core network proteins based on the underlying molecular mechanisms of resistance. Of the 14 proteins, 9 are shown to be specifically associated with survival of EGFR-mutated lung cancer cell lines. This included EGFR, GRB2, MK12, SHC1, ARAF, CD11B, ARHG5, GLU2B, and CD11A. With the use of a drug network associated with the core network proteins, we identified two compounds, midostaurin and lestaurtinib, that could overcome drug resistance through direct EGFR inhibition when combined with erlotinib. Our results, enabled by interactome mapping, suggest new targets and combination therapies that could circumvent EGFR TKI resistance.",
author = "Jiannong Li and Keiryn Bennett and Alexey Stukalov and Bin Fang and Guolin Zhang and Takeshi Yoshida and Isamu Okamoto and Kim, {Jae Young} and Lanxi Song and Yun Bai and Xiaoning Qian and Bhupendra Rawal and Michael Schell and Florian Grebien and Georg Winter and Uwe Rix and Steven Eschrich and Jacques Colinge and John Koomen and Giulio Superti-Furga and Haura, {Eric B.}",
year = "2013",
month = "11",
day = "5",
doi = "10.1038/msb.2013.61",
language = "English",
volume = "9",
journal = "Molecular Systems Biology",
issn = "1744-4292",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

AU - Li, Jiannong

AU - Bennett, Keiryn

AU - Stukalov, Alexey

AU - Fang, Bin

AU - Zhang, Guolin

AU - Yoshida, Takeshi

AU - Okamoto, Isamu

AU - Kim, Jae Young

AU - Song, Lanxi

AU - Bai, Yun

AU - Qian, Xiaoning

AU - Rawal, Bhupendra

AU - Schell, Michael

AU - Grebien, Florian

AU - Winter, Georg

AU - Rix, Uwe

AU - Eschrich, Steven

AU - Colinge, Jacques

AU - Koomen, John

AU - Superti-Furga, Giulio

AU - Haura, Eric B.

PY - 2013/11/5

Y1 - 2013/11/5

N2 - We hypothesized that elucidating the interactome of epidermal growth factor receptor (EGFR) forms that are mutated in lung cancer, via global analysis of protein-protein interactions, phosphorylation, and systematically perturbing the ensuing network nodes, should offer a new, more systems-level perspective of the molecular etiology. Here, we describe an EGFR interactome of 263 proteins and offer a 14-protein core network critical to the viability of multiple EGFR-mutated lung cancer cells. Cells with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) had differential dependence of the core network proteins based on the underlying molecular mechanisms of resistance. Of the 14 proteins, 9 are shown to be specifically associated with survival of EGFR-mutated lung cancer cell lines. This included EGFR, GRB2, MK12, SHC1, ARAF, CD11B, ARHG5, GLU2B, and CD11A. With the use of a drug network associated with the core network proteins, we identified two compounds, midostaurin and lestaurtinib, that could overcome drug resistance through direct EGFR inhibition when combined with erlotinib. Our results, enabled by interactome mapping, suggest new targets and combination therapies that could circumvent EGFR TKI resistance.

AB - We hypothesized that elucidating the interactome of epidermal growth factor receptor (EGFR) forms that are mutated in lung cancer, via global analysis of protein-protein interactions, phosphorylation, and systematically perturbing the ensuing network nodes, should offer a new, more systems-level perspective of the molecular etiology. Here, we describe an EGFR interactome of 263 proteins and offer a 14-protein core network critical to the viability of multiple EGFR-mutated lung cancer cells. Cells with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) had differential dependence of the core network proteins based on the underlying molecular mechanisms of resistance. Of the 14 proteins, 9 are shown to be specifically associated with survival of EGFR-mutated lung cancer cell lines. This included EGFR, GRB2, MK12, SHC1, ARAF, CD11B, ARHG5, GLU2B, and CD11A. With the use of a drug network associated with the core network proteins, we identified two compounds, midostaurin and lestaurtinib, that could overcome drug resistance through direct EGFR inhibition when combined with erlotinib. Our results, enabled by interactome mapping, suggest new targets and combination therapies that could circumvent EGFR TKI resistance.

UR - http://www.scopus.com/inward/record.url?scp=84889244041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889244041&partnerID=8YFLogxK

U2 - 10.1038/msb.2013.61

DO - 10.1038/msb.2013.61

M3 - Article

VL - 9

JO - Molecular Systems Biology

JF - Molecular Systems Biology

SN - 1744-4292

M1 - 705

ER -